Geographical, social or psychological conditions that may impair the protocol compliance.

Active infections or other severe medical status.

History of liver disease.

Other or concomitant treatments for melanoma or investigational product.

Previous participation in studies with adenovirus.

Virus diseases diagnosed two weeks before inclusion.

Immunosuppressive concomitant treatments

Concomitant malignant haematological disease.

Patients having family members with immunodeficient status or disease

Patients with Li Fraumeni syndrome or germinal retinoblastoma gene defects.

Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma